As expected, CRC mice after MRT+MH treatment exhibit the highest percentage of CD8+ T cells (13.21%), which is ∼2.6-, ∼2.2- and ∼1.9-fold higher than that in the Control/MR+MH/MRT+Antibiotic+MH group, respectively (Fig. 6d and Supplementary Fig. S21), addressing the significant immune mechanism of sustainable and excellent antitumor effects in MRT+MH-treated CRC mice. The gene discussed is CD8A; the disease is colorectal carcinoma.